|1.||Addy, Carol: 7 articles (08/2012 - 01/2008)|
|2.||Rosko, Kim: 6 articles (08/2012 - 01/2008)|
|3.||Li, Susie: 6 articles (10/2010 - 04/2008)|
|4.||Yuan, Jinyu: 6 articles (02/2009 - 01/2008)|
|5.||Wagner, John: 5 articles (08/2012 - 01/2008)|
|6.||Dunbar, Stephanie: 5 articles (08/2012 - 06/2008)|
|7.||Li, Hankun: 4 articles (12/2010 - 04/2008)|
|8.||Gantz, Ira: 4 articles (12/2010 - 01/2008)|
|9.||Wagner, John A: 4 articles (10/2010 - 11/2008)|
|10.||Stoch, Aubrey: 4 articles (10/2010 - 01/2008)|
|1.||Weight Loss (Weight Reduction)
05/01/2010 - "Taranabant at the 2- and 4-mg dose was effective in achieving clinically significant weight loss over 2 years and was associated with dose-related increases in adverse experiences. "
01/01/2008 - "Mechanism-of-action studies suggest that engagement of the CB1R by taranabant leads to weight loss by reducing food intake and increasing energy expenditure and fat oxidation."
01/01/2008 - "In a 12-week weight-loss study, taranabant induced statistically significant weight loss compared to placebo in obese subjects over the entire range of evaluated doses (0.5, 2, 4, and 6 mg once per day) (p < 0.001). "
08/01/2010 - "All three doses of taranabant-induced clinically meaningful and statistically significant weight loss. "
01/01/2008 - "The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake."
05/01/2010 - "A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study."
08/01/2010 - "A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study."
06/01/2010 - "A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes."
05/01/2010 - "To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients. "
06/01/2010 - "After 36 and 52 weeks, treatment with taranabant at the 1- and 2-mg doses led to clinically significant weight loss and improvement in glycaemic parameters in overweight and obese patients with T2DM that was associated with dose-related increases in adverse experiences. "
|3.||Abdominal Pain (Pain, Abdominal)
08/01/2013 - "The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice."
08/01/2013 - "Taranabant improved symptoms related to slow GI motility and abdominal pain and may become an attractive template in the development of novel therapeutics targeting IBS-C."
06/01/2010 - "Based on these data and data from other Phase III clinical studies, it was determined that the overall safety and efficacy profile of taranabant did not support further development for the treatment of obesity."
10/01/2008 - "By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed."
07/01/2008 - "These efforts resulted in the identification of the CB1R inverse agonist, taranabant, which is currently in Phase-III clinical studies for the treatment of obesity. "
04/01/2008 - "Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers."
06/01/2007 - "These studies demonstrated that MK-0364 is a highly potent and selective CB1R inverse agonist and that it is orally active in rodent models of obesity."
04/01/2010 - "Compared to placebo, taranabant 2-8 mg was associated with an increased incidence of psychiatric-related adverse events (e.g., depression, 8.2% versus 2.5%, P = 0.048), gastrointestinal-related adverse events (e.g., nausea, 49.7% versus 19.0%, P < 0.001), and flushing/hot flash adverse events (10.7% versus 1.9%, P = 0.002). "
11/01/2010 - "However, there may also be undesirable side effects (e.g., nausea, malaise, anxiety, and depression) that are produced by the current generation of CB1 inverse agonists such as rimonabant and taranabant. "
06/01/2010 - "After 52 weeks, the incidences of adverse experiences classified in the gastrointestinal (diarrhoea, nausea, vomiting), nervous system-related (dizziness, sensory-related), and psychiatric (irritability, depression-related) organ systems were numerically higher or statistically significantly higher in all taranabant groups compared with the placebo group. "
08/01/2010 - "Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group. "
03/01/2009 - "However, rimonabant's market withdrawal in the European Union and suspension of rimonabant's, taranabant's, and otenabant's ongoing development programs have highlighted some adverse clinical side effects (especially nausea and psychiatric disturbances) of CB1 receptor antagonists/inverse agonists. "
|2.||CB1 Cannabinoid Receptor (CB1 Receptor)
|9.||8- chloro- 2,3,4,5- tetrahydro- 1- methyl- 1H- 3- benzazepine
|1.||Drug Therapy (Chemotherapy)